Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aprea Presents Preclinical Data at AACR

Published: Thursday, April 11, 2013
Last Updated: Thursday, April 11, 2013
Bookmark and Share
Strong synergistic effect with APR-246 and cisplatin.

Aprea AB has presented preclinical data at the American Association for Cancer Research (AACR) meeting in Washington, DC, USA.

The results from these studies show that Aprea’s lead candidate APR-246, a compound that reactivates mutant p53, acts synergistically with platinum compounds.

Aprea, which is part of the Karolinska Development portfolio, is now preparing a Phase II study with APR-246 in platinum resistant ovarian cancer.

The title of Aprea’s poster presentation at AACR was “Strong synergistic effects with cisplatin and APR-246, a novel compound reactivating mutant p53, in ovarian cancer cell lines and primary cells from patients”.

In the studies, the anticancer effect of APR-246 alone, and in combination with platinum compounds, on ovarian cancer cells were investigated.

The results show that APR-246 acts synergistically with platinum compounds and reverses the cisplatin-sensitivity to cisplatin-resistant p53 mutant ovarian cancer cells.

Aberrations in p53 are common in many cancer forms and are associated with increased resistance to standard chemotherapy resulting in a poor prognosis for the patient. About 60% of ovarian cancer patients have p53 mutations.

Mikael von Euler, CMO of Aprea, commented; “We are very pleased with this comprehensive set of preclinical data supporting our planned Phase II study in platinum-resistant Epithelial Ovarian Cancer (EOC) patients who are candidates for further platinum-based chemotherapy. APR-246 has the potential to be an important new treatment for these patients with high unmet medical need”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aprea Granted European Orphan Drug Designation for APR-246 in Ovarian Cancer
Company is currently conducting a Phase Ib/II trial of APR-246.
Saturday, January 24, 2015
Aprea Strengthens its Board
Company elects Bernd R. Seizinger as new member of the board.
Tuesday, January 21, 2014
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!